Hanall Biopharma Co. Ltd.

Daewoong Pharmaceutical has received approval for the clinical trial plan of its inflammatory bowel disease treatment, while Hanall Biopharma's global partner met key evaluation criteria in the clinical trial for its treatment of refractory rheumatoid arthritis. Efforts are being made to enhance the convenience of administering biopharmaceuticals.

datasom13 Nov 2026Positive

Daewoong Bio's 'Wecap', Hanol BioPharma's 'Apsito', and Ianthe Therapeutics' 'Beloxcap', all 40mg products with the same active ingredient, adjusted their listed price to 1860 Won starting in June. Daewoong Pharmaceutical's use of flexible pricing contracts is not limited to the fexuprazan category...

hitnews13 Nov 2026Neutral

In South Korea, HanAll Biopharma and Celltrion are noted as leading companies entering the development of FcRn inhibitors. FcRn is a receptor that extends the lifespan of immunoglobulin G (IgG) antibodies in the body, and blocking it can reduce pathogenic autoantibodies...

view.asiae12 Nov 2026Neutral

HanAll Biopharma has shifted the global development focus of its autoimmune disease drug candidate 'IMVT-1402' to four key indications, including Graves' disease and refractory rheumatoid arthritis. The U.S. partner...

newsmp12 Nov 2026Neutral

Ingenia Therapeutics is focusing on independent development, while Hanall Biopharma is emphasizing joint research with partners. According to industry sources on the 11th, Ingenia Therapeutics has recently received a glaucoma candidate substance 'IGT-302' from its partner MSD.

sidae11 Nov 2026Neutral

No stocks fell more than 5%, while Hanall Biopharma (+6.32%) and Hanmi Pharmaceutical (+5.32%) both recorded gains exceeding 5% in the KOSDAQ market. There were no stocks that fell more than 5%.

newsmp11 Nov 2026Positive

Hanall Biopharma's stock price increased by 6.32% from 46,700 KRW to 49,650 KRW. G2G Biopharma's stock price rose by 5.84% from 35,100 KRW to 37,150 KRW. Inventera's stock price grew by 5.67% from 7,410 KRW to 7,830 KRW. Pharmicell's stock price...

medipana11 Nov 2026Positive

Hanol BioPharma announced the success of its Phase 2 clinical trial for a candidate treatment for autoimmune diseases, but it is still expected to record an annual net loss this year, leaving performance pressures and high valuation burdens as ongoing challenges.

newsquest11 Nov 2026Negative

Hanol BioPharma has reportedly achieved results exceeding expectations in clinical trials for its new drug candidate 'IMVT-1402' targeting refractory rheumatoid arthritis. Heo Hye-min, a researcher at Kiwoom Securities, stated in a report on the 11th that "Hanol BioPharma's U.S. partner...

businesspost11 Nov 2026Positive

Hanall Biopharma's 'Aimeroprubate (IMVT-1402)' has achieved primary endpoints in a Phase 2b trial for refractory rheumatoid arthritis, and topline results for Graves' disease and myasthenia gravis are also expected next year, indicating continued clinical momentum.

sedaily11 Nov 2026Positive

Hanall Biopharma's autoimmune disease treatment has shown high therapeutic effects in rheumatoid arthritis patients who did not respond to existing medications. With the announcement of clinical trial results confirming the drug's efficacy, the securities industry...

newspim11 Nov 2026Positive

Hanall Biopharma's autoimmune disease treatment 'IMVT-1402' has demonstrated efficacy in high-dose continuous administration in clinical trials for refractory rheumatoid arthritis, raising expectations for follow-up trials. On the 11th, Hana Securities commented on Hanall Biopharma...

press911 Nov 2026Positive

On November 11, Kyobo Securities stated that Hanol BioPharma's new drug candidate 'IMVT-1402' has confirmed efficacy in clinical trials for treatment-resistant rheumatoid arthritis, noting that attention should be paid to additional clinical results expected next year. The current stock price is seen as an attractive buy...

popcornnews11 Nov 2026Positive

Immunovant, HanAll Biopharma's global partner, announced on the 10th that it has met the primary endpoint in its Phase 2b clinical trial of IMVT-1402 for patients with difficult-to-treat rheumatoid arthritis (D2T RA).

docdocdoc11 Nov 2026Positive

HanAll Biopharma's global partner Immunovant's autoimmune disease treatment candidate 'Imunoprivate (IMVT-1402)' has met the primary endpoint in a clinical trial for refractory rheumatoid arthritis. HanAll Biopharma (co-CEOs...

thefirstmedia10 Nov 2026Positive

Hanall Biopharma's global partner Immunovant announced on the 9th (U.S. local time) during its quarterly earnings report that the clinical trial for the new drug 'Imeglimin (IMVT-1402)' in patients with refractory rheumatoid arthritis met its primary endpoint...

getnews10 Nov 2026Positive

HanAll Biopharma's new drug candidate 'Imeropruvate (IMVT-1402)' has met the primary endpoint in a clinical trial for patients with intractable rheumatoid arthritis who did not respond adequately to existing targeted therapies. The high-dose group showed results at the 28-week mark...

megaeconomy10 Nov 2026Positive

Hanol BioPharma (009420) surged due to the clinical success of its global partner in treating refractory rheumatoid arthritis. Partner Immunovant reported that its next-generation FcRn inhibitor, imlifidase (IMVT-1402), met its primary endpoint in clinical trials...

biotimes10 Nov 2026Positive

Hanall Biopharma. Bio and healthcare companies are achieving results in confirming the clinical efficacy of new drug candidates, researching functional materials, and obtaining overseas drug approvals. Improvements in clinical indicators for treatments of intractable diseases and the functionality of probiotics...

kdfnews10 Nov 2026Positive

HanAll Biopharma's global partner Immunovant has met key endpoints in clinical trials for a candidate treatment for refractory rheumatoid arthritis. High response rates were observed even in patient groups that did not respond to existing targeted therapies.

thepublic10 Nov 2026Positive

HanAll Biopharma (009420)'s autoimmune disease treatment candidate Imaroprat (IMVT-1402) has met key evaluation criteria in a clinical trial for treatment-resistant rheumatoid arthritis patients who do not respond to existing therapies.

news110 Nov 2026Positive

As interest in clinical trials for autoimmune disease drugs rises, Hanall Biopharma's stock price has moved. Investors are checking both the price and trading volume. As of 2:17 PM, Hanall Biopharma's bid on the KOSDAQ was 47,000 KRW.

job-post10 Nov 2026Positive

HanAll Biopharma CI. [HanAll Biopharma] HanAll Biopharma's U.S. partner Immunovant has achieved success in the clinical trial of the autoimmune disease treatment candidate 'Imeropruvate (IMVT-1402)' for treatment-resistant rheumatoid arthritis, meeting the primary efficacy evaluation variable...

ziksir10 Nov 2026Positive

Hanol BioPharma is up over 26% following news that its global partner has met the primary endpoint in a clinical trial for a new drug for treatment-resistant rheumatoid arthritis. As of 2:12 PM on the 10th, Hanol BioPharma is trading higher than the previous day on the KOSDAQ.

namdonews10 Nov 2026Positive

HanAll Biopharma logo. Photo=HanAll Biopharma. HanAll Biopharma (co-CEOs Park Soo-jin and Park Seung-guk) announced that its global partner has met the primary endpoint in a clinical trial of a new drug candidate for patients with refractory rheumatoid arthritis.

bizwnews10 Nov 2026Positive

Hanall Biopharma announced on the 10th that its global partner Immunovant has met the primary endpoint in the clinical trial of imlifidase (IMVT-1402) for patients with refractory rheumatoid arthritis (D2T RA). This trial is...

kormedi10 Nov 2026Positive

Hanol BioPharma's candidate for the treatment of refractory rheumatoid arthritis has met key evaluation criteria in clinical trials, leading to a strong performance in its stock. As of 11:07 AM on the 10th, Hanol BioPharma (009420) stock price has increased compared to the previous trading day...

etnews10 Nov 2026Positive

New Daily reporter Ahn Kyung-jin = HanAll Biopharma has secured positive results in a Phase 2 clinical trial for its antibody drug exported 9 years ago, targeting refractory rheumatoid arthritis. Following the high treatment response rate observed in initial dosing results last May, the drug...

newdaily10 Nov 2026Positive

HanAll Biopharma's Imaroprant, licensed to Immunovant in the U.S., has shown significant efficacy in clinical results for refractory rheumatoid arthritis. According to industry sources on the 10th, Immunovant is pursuing indications for refractory rheumatoid arthritis...

dailian10 Nov 2026Positive

HanAll Biopharma's autoimmune disease treatment candidate 'Imeropruvate' (IMVT-1402) has met the primary endpoint in a Phase 2 clinical trial for patients with refractory rheumatoid arthritis. However, the evaluation of disease activity...

mt10 Nov 2026Positive